Business ❯Pharmaceutical Industry ❯Mergers and Acquisitions

Bristol Myers Squibb

Karuna Therapeutics Acquisition of Karuna Therapeutics

Bristol Myers Squibb Acquires Karuna Therapeutics in $14 Billion Deal

Karuna's Antipsychotic Drug KarXT Under FDA Review, Decision Expected by September 2024